The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Adam J. Fein, Ph.D.
Drug Channels Institute

March 2021

Full report available at https://drugch.nl/pharmacy
Copyright © 2021 by Pembroke Consulting, Inc., d/b/a Drug Channels Institute. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

If you would like to quote from or otherwise cite the report, here is a suggested sample citation:


The complete End User License Agreement is available at: http://drugch.nl/2021EULA
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles. Dr. Fein has contributed to and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBM’s, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife and business partner, Paula.

Contact information
  Adam J. Fein, Ph.D.
  Drug Channels Institute
  1515 Market Street, Suite 1660
  Philadelphia, PA 19102
  Phone: 215-523-5700
  Website: www.DrugChannelsInstitute.com
  Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels website for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—into interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. Click here to view a module list.

These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

Drug Channels Institute also hosts live video webinars during which Dr. Fein discusses trends and policies that affect the pharmaceutical industry and its channels. Click here to view our current and previous video webinars.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 1660
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.drugchannelsinstitute.com
Email: paula@drugchannels.net
INTRODUCTION AND GUIDE TO THE 2021 REPORT


However, this period also demonstrated the underlying resilience of U.S. distribution and dispensing channels for prescription drugs. Pharmaceutical wholesalers maintained shipments and operational capacity. Payers and pharmacy benefit managers (PBMs) waived benefit limitations so patients could access therapies. Pharmacies and pharmacists stepped up as critical providers of medications and are playing a crucial role in administering COVID-19 vaccines.

In the midst of the pandemic, the industry continues to confront a diverse set of commercial, political, and legal challenges. They are among the many issues we consider in this report:

- Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached a record $465 billion in 2020. Specialty drugs accounted for nearly 40% of these revenues—and an even greater share of payers’ net prescription costs.

- Insurers, PBMs, and specialty pharmacies have combined into vertically integrated organizations. The COVID-19 pandemic has slowed or delayed some companies’ efforts to achieve vertical synergies. However, these organizations are still poised to exert greater control over patient access, sites of care, dispensing locations, and pricing.

- Payers and PBMs are tightening their management of specialty drugs, thereby pressuring independent specialty pharmacies, physician practices, and hospitals. The specialty pharmacy industry has become more concentrated, due to the acquisition of many large independent specialty pharmacies.

- The pharmacy industry remains intensely competitive, pressuring prescription profits. Retail pharmacies are undergoing a shakeout that is reducing the number of U.S. pharmacy locations, as small chains and supermarkets sell to larger competitors.

- List prices for brand-name drugs—which directly impact the revenues and profits of pharmacies and PBMs—are growing more slowly than they have historically. However, brand-name drugs’ net prices (after rebates and discounts) have declined for the third year. Consequently, growth in the number of people being treated and the number of prescriptions being dispensed has become a key driver of rising drug spending.

- Generic market pricing has stabilized after the periods of rapid inflation and deflation. Pharmacy profits have benefited from this stability, though low generic prices are limiting pharmacies’ revenues and gross profits from these prescriptions.
• Patients taking specialty drugs faced high out-of-pocket costs due to benefit design that favors deductibles and coinsurance spending. At the same time, a growing share of prescriptions is being dispensed with no patient out-of-pocket expense.

• Controversy over copay accumulator and maximizer programs is rising, as plans attempt to reduce their spending by accessing manufacturers’ patient support funds.

• The gross-to-net bubble, which measures total rebates and discounts paid by manufacturers, reached $187 billion for patent-protected brand-name drugs in 2020. Regulatory efforts to remove the role of rebates in the Medicare Part D program have been delayed, perhaps indefinitely.

• Regulators and lawmakers continue to scrutinize PBMs’ profit models and incentives. Disclosures about PBMs’ unexpectedly large profits in Managed Medicaid programs have triggered several larger states to carve-out pharmacy to fee-for-service Medicaid.

• The 340B Drug Pricing Program is now roughly the size of the nation’s Medicaid outpatient drug market. Pharmacies’ role in—and profits from—the 340B program were disrupted during 2020, when some manufacturers began limiting prescriptions dispensed via contract pharmacies. These highly controversial actions have triggered litigation and raised the prospect of greater government oversight of the 340B program.

• Amazon’s pharmacy strategy has become clearer, though the company is still not poised to fundamentally disrupt the existing drug channel. Venture capital firms expanded their financing of numerous digital pharmacies that are attempting to alter conventional ways of doing business.

• The retail pharmacy clinic model is fading in favor of locations with broader healthcare services. Pharmacies are competing more directly with urgent care clinics and other healthcare providers.

• The federal government has finalized regulations for the commercial importation of drugs intended for Canada. However, industry opposition and practical challenges will limit any impact on pharmacies, PBMs, and U.S. drug prices.

• Federal legislative action regarding drug prices remains highly uncertain. However, states have already enacted a total of more than 160 laws targeting various aspects of the U.S. drug channel and its participants.

• New cell and gene therapies have been launched. Specialty pharmacies that are not owned or closely affiliated with a payer seem likely to play a limited role in these emerging distribution and reimbursement channel models.
Understanding an Evolving Marketplace

The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—our 12th edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique resource is your ultimate guide to the complex web of interactions within U.S. prescription drug channels.

This definitive, nonpartisan report includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and more. The report synthesizes a wealth of statistical data, research studies, financial information, and my own extensive business consulting experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

Thousands of companies operate within the U.S. system, enabling more than 6.1 billion equivalent prescriptions to be dispensed and paid. The table below highlights the largest public companies that operate in the drug channel. Many of these firms are among the largest businesses on the Fortune 500 list.

**Major Public Companies Operating in U.S. Drug Channels**

<table>
<thead>
<tr>
<th>Company</th>
<th>Stock Ticker</th>
<th>Primary U.S. Channel Role(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amazon</td>
<td>AMZN</td>
<td>Mail pharmacy</td>
</tr>
<tr>
<td>CVS Health</td>
<td>CVS</td>
<td>Insurer/PBM/Chain drugstore/Mail &amp; specialty pharmacy/Long-term care pharmacy</td>
</tr>
<tr>
<td>GoodRx</td>
<td>GDRX</td>
<td>Discount card provider</td>
</tr>
<tr>
<td>Kroger</td>
<td>KR</td>
<td>Supermarket with pharmacy/PBM/Specialty pharmacy</td>
</tr>
<tr>
<td>Rite Aid Corporation</td>
<td>RAD</td>
<td>Chain drugstore/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Walgreens Boots Alliance</td>
<td>WBA</td>
<td>Chain drugstore/Mail &amp; specialty pharmacy/Long-term care pharmacy</td>
</tr>
<tr>
<td>Walmart Stores, Inc.</td>
<td>WMT</td>
<td>Mass merchant with pharmacy/Specialty pharmacy</td>
</tr>
<tr>
<td>Anthem</td>
<td>ANTM</td>
<td>Insurer/PBM</td>
</tr>
<tr>
<td>Centene</td>
<td>CNC</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Cigna</td>
<td>CI</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Humana</td>
<td>HUM</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>UnitedHealth Group</td>
<td>UNH</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>AmerisourceBergen</td>
<td>ABC</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
<tr>
<td>Cardinal Health</td>
<td>CAH</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>McKesson Corporation</td>
<td>MCK</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
</tbody>
</table>

*PBM = pharmacy benefit manager
Source: Drug Channels Institute research*

These and other companies discussed in this report operate within a complex distribution, payment, and reimbursement system, illustrated on the next page.
The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs

The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses and analyzes the key channel flows illustrated above:

- **Product Movement**, which traces shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. Retail, mail, long-term care, and specialty pharmacies mark the final step in which a prescription is dispensed to a patient.

- **Financial Flows**, which transfer money from third-party payers to pharmacy benefit managers (PBMs), which in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers to PBMs in the form of rebates and fees. The PBMs share most of these payments with plan sponsors, reducing plans’ net prescription costs. Manufacturers’ payments to PBMs and other third-party payers do not flow through wholesale or retail channels.

- **Contractual Relationships**, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

In Sections II and III of the report, we revisit this chart to link each flow with the corresponding report chapters that explain and analyze it. To further explain these flows and their corresponding report chapters, the chart appears as **Exhibit 66** (page 108).
What’s New in the 2021 Report

The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers retains the overall structure we employed in last year’s edition. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

The most notable new material throughout this 2021 edition addresses COVID-19 and its impact on the pharmacy and PBM industries. Given this uncertainty, we plan to revisit the topic in future editions. We will also continue to monitor these trends on Drug Channels.

Many sections and chapters have been expanded and/or reorganized to better cover the latest industry developments. Changes and updates in this 2021 edition include:

- Chapter 1 includes new material about healthcare and clinical services at retail locations, as well as additional data about vaccine and immunization services.

- Chapter 2 incorporates new data analyses that address COVID-19 and its impact on the pharmacy industry.

- We have further expanded and updated our Chapter 3 analyses of the specialty market, including additional information about PBMs, hospitals, and specialty hubs.

- Chapter 4 includes new estimates of health insurance coverage and our projections of how COVID-19 will alter these figures. We also incorporate CMS’s comprehensive revision to national healthcare spending data, including outpatient prescription drugs.

- Section 4.3. has been split into two sections to better cover the cash-pay prescription market and the role of discount cards.

- Chapter 5 expands our coverage of PBMs to include additional market participants. We have also updated and expanded our analyses of spread pricing in Managed Medicaid.

- In Chapter 6, the data on patient out-of-pocket expenses include new information on cost sharing, coinsurance, and average out-of-pocket spending.

- Chapter 8 contains new material discussing the differences between pharmacy reimbursement under fee-for-service and managed care approaches in Medicaid.

- Chapter 9 offers a new section on pricing for the Department of Veterans Affairs.

- Chapter 11 includes significant new information about pharmacies’ profits from the 340B Drug Pricing Program.
• Chapter 12, which covers the industry outlook and emerging trends, has been significantly updated to reflect developments that have occurred since the preceding edition of this report.

• Throughout the report, we have added new industry data sources, deepened our coverage of many topics, and added more trending information. There are 211 exhibits in the 2021 edition, compared with 203 in the 2020 edition and 180 in the 2019 edition.

Structure of the 2021 Report

This report analyzes the industry in 3 major sections, comprising 12 total chapters:

SECTION I: THE U.S. PHARMACY INDUSTRY

• Chapter 1: Industry Overview (page 12) defines the industry and its regulatory framework, describes the different products and prescriptions that a pharmacy dispenses, provides data on traditional and specialty prescription costs, delineates among different pharmacy industry participants, and quantifies differences among dispensing formats. This chapter includes our analysis of pharmacist-provided clinical services (including medication therapy management services) and healthcare clinics.

• Chapter 2: Pharmacy Industry Market Structure (page 46) analyzes the industry’s prescription and revenue growth trends. It identifies the largest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and for the major national companies.

• Chapter 3: Specialty Drugs and Specialty Pharmacies (page 69) provides a comprehensive overview of the pharmacies dispensing specialty medications. It includes our exclusive analyses of national market share for pharmacy-dispensed specialty drugs and accreditation trends among pharmacies. It also provides a competitive analysis of the various organizations that compete to dispense specialty medications. The chapter reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs, explains the role of service fees, and profiles the specialty hub services market.

SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS

• Chapter 4: Payment and Spending for Prescription Drugs (page 109) examines the primary payers for prescription drugs at retail, mail, long-term care, and specialty pharmacies. It analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. Chapter 4 also reviews the cash-pay prescription market and the use of discount card programs.

• Chapter 5: Pharmacy Benefit Management (page 130) identifies the services and roles of pharmacy benefit managers (PBMs). Chapter 5 also analyzes the structure of the PBM
industry and reviews the business strategies of the largest PBMs. It describes the relationship between PBMs and the pharmacies that participate in a PBM’s network, reviews how pharmacy services administrative organizations (PSAOs) intermediate between retail pharmacies and PBMs, and explains how plan sponsors compensate PBMs for benefit management services. Chapter 5 includes a detailed review of PBMs’ spread pricing profits from Managed Medicaid programs. This material appeared in Chapter 11 of the 2020 edition.

- **Chapter 6: Consumer Copayments and Coinsurance** (page 161) analyzes the benefit designs and plan structures that determine patients’ out-of-pocket spending for the major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We explore manufacturers’ out-of-pocket payment support programs, explain the emergence and use of copay accumulators and maximizers, and provide data on patient out-of-pocket expenses. We also explore how benefit design affects patients’ costs.

- **Chapter 7: Narrow Pharmacy Networks** (page 198) analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for pharmacies in commercial health plans and Medicare Part D. We review mail and retail pharmacies as narrow network options for maintenance prescriptions. This chapter also evaluates the latest data on payer-defined networks for specialty drug dispensing in commercial health plans and for buy-and-bill channels.

**SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK**

- **Chapter 8: Prescription Reimbursement by Third-Party Payers** (page 222) explains the formulas and methodologies for computing a pharmacy’s revenue from brand-name, generic, and specialty prescriptions. It also delves into maximum allowable cost (MAC) prices as well as the regulations and laws related to MAC prices. This chapter compares traditional list price methods with acquisition-cost reimbursement approaches now utilized in fee-for-service Medicaid programs. We also review the economics of mail vs. retail pharmacies for payers and consumers.

- **Chapter 9: Drug Pricing, Rebates, and Payer Costs** (page 237) explores rebates in commercial health plans, Medicare Part D, Medicaid, and the Department of Veterans Affairs. It explains how PBMs negotiate with manufacturers, analyzes trends in list and net drug prices, and describes the gross-to-net bubble phenomenon. The chapter explains how plan sponsors use rebates, the role of point-of-sale rebates, and controversies over rebates. The chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor’s net costs for a typical traditional and specialty prescription.

- **Chapter 10: Relationships With Pharmaceutical Wholesalers** (page 270) explores pharmacies’ interactions with their primary wholesale suppliers of drugs. It explains
wholesalers’ channel roles and services, identifies the largest wholesale suppliers, and analyzes how wholesalers affect pharmacies’ acquisition costs for drugs. We present our latest data on pharmacy group purchasing organizations and the generic sourcing relationships between wholesalers and large pharmacies.

- **Chapter 11: Pharmacy and Prescription Profitability** (page 282) unites the reimbursement and cost discussion from Chapter 8 and Chapter 10 by presenting the latest available data on pharmacy and prescription profitability. This chapter documents overall drugstore profitability, pharmacy margins for prescriptions from different dispensing formats, profit differences between brand and generic prescriptions, and PBMs’ gross profits from network and mail pharmacies. Chapter 11 also includes material on the direct and indirect remuneration (DIR) fee payments that pharmacies make to PBMs and health plans. Finally, we consider pharmacies’ role and profits in the 340B Drug Pricing Program.

- **Chapter 12: Outlook and Emerging Trends** (page 315) presents the outlook for net prescription drug spending and our updated projections for the pharmacy industry’s product mix and revenues in 2025. This chapter also considers future trends, including pharmacy-dispensed biosimilars, importation, state and federal legislation, cell and gene therapies, and such new entrants as Amazon and venture-backed startup pharmacies.

**How to Use the 2021 Report**

*The chapters are self-contained and do not need to be read in order.* We include extensive internal clickable hyperlinks to help you navigate the entire document and customize it to your specific needs. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

There are more than 700 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations used within it. To search the entire PDF document for every occurrence of a word or phrase, use the following shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about *The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers*.

Adam J. Fein
March 2021

P.S. [Click here for post-publication errata.](#)
# CONTENTS

## PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES

1

## SECTION I: THE U.S. PHARMACY INDUSTRY

11

### Chapter 1: Industry Overview

12

1.1. Pharmacy Fundamentals ........................................................................................................ 12

1.1.1. Defining the Practice of Pharmacy ....................................................................................... 12

1.1.2. Pharmacies and the Drug Supply Chain Security Act .......................................................... 13

1.2. The Products That Pharmacies Dispense .................................................................................. 17

1.2.1. Brand vs. Generic Drugs ....................................................................................................... 17

1.2.2. Traditional vs. Specialty Drugs .............................................................................................. 20

1.2.3. Top Therapy Classes and Average Prescription Costs .......................................................... 23

1.3. Pharmacy Industry Participants ............................................................................................. 25

1.3.1. Pharmacy Dispensing Formats ............................................................................................. 25

1.3.2. Differences Among Outpatient Retail Dispensing Formats .................................................... 26

1.3.3. Pharmacist Salaries and Employment ................................................................................... 31

1.4. Healthcare and Clinical Services ............................................................................................ 34

1.4.1. Retail Clinics and Healthcare Services .................................................................................. 34

1.4.2. Medication Therapy Management (MTM), Clinical Services, and Provider Status ............ 38

1.4.3. Immunization and Vaccination .............................................................................................. 43

### Chapter 2: Pharmacy Industry Market Structure .................................................................. 46

2.1. Industry Trends ......................................................................................................................... 46

2.1.1. Total and 30-Day Equivalent Prescriptions .......................................................................... 46

2.1.2. Prescription Dispensing Revenues ....................................................................................... 49

2.2. National Prescription Dispensing Market Share, by Company ............................................. 50

2.3. Trends by Dispensing Format ................................................................................................ 52

2.3.1. Long-Term Trends in Revenues and Prescriptions ................................................................. 52

2.3.2. Market Changes in 2020 ..................................................................................................... 53

2.3.3. National Retail Chains ......................................................................................................... 56

2.3.4. Regional Chains ................................................................................................................. 61

2.3.5. Independent Pharmacies .................................................................................................... 63
Chapter 3: Specialty Drugs and Specialty Pharmacies .......................................................... 69

3.1. Specialty Pharmacies ........................................................................................................ 69

3.1.1. Defining Specialty Pharmacy ..................................................................................... 69

3.1.2. Clinical and Data Services ......................................................................................... 70

3.1.3. Accreditation .............................................................................................................. 72

3.2. Specialty Pharmacy Market Structure ........................................................................... 75

3.2.1. Specialty Pharmacy Industry Market Size ................................................................ 75

3.2.2. Number of Accredited Specialty Pharmacies ............................................................ 77

3.2.3. National Market Share for Specialty Dispensing, by Company ............................. 78

3.2.4. Mergers and Acquisitions Among Specialty Pharmacies in 2020 ......................... 79

3.3. Trends by Specialty Dispensing Format .......................................................................... 82

3.3.1. Overview of the 2020 Marketplace ............................................................................ 82

3.3.2. Pharmacy Benefit Managers and Health Plans ....................................................... 85

3.3.3. Independent Specialty Pharmacies ........................................................................... 87

3.3.4. Retail Chains ............................................................................................................. 88

3.3.5. Hospitals and Health Systems .................................................................................. 91

3.3.6. Physician Practices and Other Providers ................................................................. 96

3.3.7. Pharmaceutical Wholesalers .................................................................................... 99

3.4. Manufacturer Channel Strategies for Specialty Drugs ................................................. 100

3.4.1. Manufacturer-Defined Dispensing Networks and REMS ..................................... 100

3.4.2. Compensation for Clinical and Data Services ......................................................... 102

3.4.3. Specialty Hub Services and Leading Providers ....................................................... 105

SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS ........................................ 108

Chapter 4: Payment and Spending for Prescription Drugs ................................................. 109

4.1. U.S. Healthcare Spending .............................................................................................. 109

4.1.1. Enrollment in Health Insurance and COVID-19 Impact ............................................ 109

4.1.2. Prescription Drugs and U.S. Healthcare Spending ............................................... 112

4.2. Payer and Spending Trends ........................................................................................... 114

4.2.1. Payment for Outpatient Prescription Drugs ............................................................... 114

4.2.2. Trends in Drug Spending, by Payer ......................................................................... 117
Chapter 6: Consumer Copayments and Coinsurance

6.1. Cost Sharing in Pharmacy Benefit Design ................................................................. 161
   6.1.1. Employer-Sponsored Health Plans ........................................................................ 162
   6.1.2. Health Insurance Marketplace Plans ................................................................... 168
   6.1.3. Medicare Part D ..................................................................................................... 170
   6.1.4. Medicaid ................................................................................................................ 176

6.2. Manufacturer Out-of-Pocket Payment Support ......................................................... 176
   6.2.1. Copayment Offset Programs .................................................................................. 177
   6.2.2. Copay Accumulator Adjustment and Copay Maximizers ..................................... 181
6.2.3. Patient Assistance Programs ................................................................. 186
6.3. Out-of-Pocket Expenses ........................................................................... 187
6.3.1. Actual Patient Out-of-Pocket Spending on Prescriptions ....................... 187
6.3.2. Consequences of Pharmacy Benefit Designs .......................................... 191

Chapter 7: Narrow Pharmacy Networks ......................................................... 198

7.1. Overview of Pharmacy Benefit Network Models ....................................... 198
7.1.1. Network Options ..................................................................................... 198
7.1.2. The Economics of Narrow Pharmacy Networks ....................................... 200
7.1.3. Legal and Regulatory Restrictions on Network Design ......................... 201

7.2. Retail Pharmacy Networks ....................................................................... 203
7.2.1. Preferred Retail Networks in Medicare Part D ....................................... 203
7.2.2. Narrow Retail Networks in Commercial and Other Plans ...................... 210
7.2.3. Narrow Networks for Maintenance Prescriptions ................................ 212

7.3. Payer-Defined Specialty Dispensing Networks ........................................ 215
7.3.1. Commercial Health Plans ..................................................................... 215
7.3.2. Specialty Pharmacies’ Role in Buy-and-Bill Channels ......................... 216

SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK .................... 221

Chapter 8: Prescription Reimbursement by Third-Party Payers ....................... 222

8.1. The Basics of Prescription Reimbursement .............................................. 222
8.1.1. Estimated Acquisition Cost (EAC) ......................................................... 222
8.1.2. Dispensing Fees ..................................................................................... 224
8.1.3. Service and Data Fees ......................................................................... 225

8.2. Reimbursement for Brand-Name and Specialty Prescriptions .................... 226
8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices .......... 226
8.2.2. AWP Discounts for Pharmacy Reimbursement .................................... 227
8.2.3. Why Mail Pharmacies Accept Lower Reimbursements ....................... 229

8.3. Reimbursement for Generic Prescriptions ............................................... 230
8.3.1. AWP Discounts for Generic Prescriptions ............................................ 230
8.3.2. Maximum Allowable Cost (MAC) Limits and Generic Effective Rate (GER) ............. 231
8.3.3. Regulations and Laws Regarding MAC Limits ..................................... 232
8.3.4. Medicaid and Federal Upper Limits ................................................... 233
8.4. Acquisition Cost Reimbursement

Chapter 9: Drug Pricing, Rebates, and Payer Costs

9.1. Rebates to Third-Party Payers

9.1.1. How Commercial Payers Access Rebates

9.1.2. Rebates and DIR in Medicare Part D

9.1.3. The Medicaid Drug Rebate Program

9.1.4. Department of Veterans Affairs

9.2. Gross and Net Drug Pricing

9.2.1. List vs. Net Drug Prices

9.2.2. The Gross-to-Net Bubble in 2020

9.3. Issues with the Rebate System

9.3.1. How Plan Sponsors Use Rebates

9.3.2. Point-of-Sale (POS) Rebates

9.3.3. Controversies Over Rebates and Rebate Reform

9.4. How Prescription Reimbursement, Formulary Rebates, Consumer Copayments, and PBM Expenses Affect Plan Sponsor Costs

Chapter 10: Relationships With Pharmaceutical Wholesalers

10.1. Overview of Wholesale Drug Channels

10.1.1. Industry Participants

10.1.2. Product Distribution

10.1.3. Financial Intermediation

10.1.4. Other Services for Pharmacies, Providers, and Manufacturers

10.1.5. Impact on Pharmacy Reimbursement

10.2. Determinants of Pharmacies’ Acquisition Costs

10.2.1. Wholesaler Pricing of Brand-Name Drugs to Pharmacies

10.2.2. Pharmacy Group Purchasing Organizations

10.2.3. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies

Chapter 11: Pharmacy and Prescription Profitability

11.1. Overall Drugstore Gross Margins

11.1.1. Industry Averages

11.1.2. Chain Drugstores
11.2. Pharmacy Per-Prescription Profits ................................................................. 285
  11.2.1. Sources of Per-Prescription Profits ......................................................... 285
  11.2.2. Average Per-Prescription Profits for Pharmacies ....................................... 287
  11.2.3. PBM Gross Profits from Network and PBM-Owned Pharmacies ...................... 289
  11.2.4. The Impact of Brand-Name Inflation on Prescription Profits ........................... 291
  11.2.5. Pharmacy Profits With Acquisition Cost-Based Reimbursement ....................... 292
11.3. Lifecycle Profitability for Generic Prescriptions ............................................... 294
11.4. Pharmacy DIR Fees in Medicare Part D Networks ........................................... 298
  11.4.1. Computation of Pharmacy DIR Fees ......................................................... 299
  11.4.2. Financial Impact of Pharmacy DIR Fees ...................................................... 300
  11.4.3. The Outlook for Pharmacy DIR Fees .......................................................... 302
11.5. Pharmacy Profits from the 340B Drug Pricing Program .................................... 303
  11.5.1. Overview of the 340B Program and Drug Prices ........................................ 303
  11.5.2. Companies Participating As 340B Contract Pharmacies ................................ 305
  11.5.3. Flow of Funds for a 340B Contract Pharmacy Network .................................. 309
  11.5.4. Pharmacy and Covered Entity Profits from 340B Prescriptions ....................... 310
Chapter 12: Outlook and Emerging Trends ..................................................................... 315
12.1. Industry Outlook ............................................................................................... 315
  12.1.1. U.S. Net Spending on Outpatient Prescriptions from 2020 to 2025 .................. 315
  12.1.2. Pharmacy Revenues from Traditional vs. Specialty Drugs in 2025 .................. 317
12.2. Drug Prices ...................................................................................................... 319
  12.2.1. The Outlook for Brand-Name Drug Prices ...................................................... 319
  12.2.2. The Outlook for Generic Drug Prices ............................................................ 320
12.3. The Outlook for Biosimilars .............................................................................. 323
  12.3.1. 2020 Update on the Biosimilar Market ....................................................... 323
  12.3.2. Biosimilars Under the Pharmacy Benefit ....................................................... 324
12.4. Emerging Trends ............................................................................................. 327
  12.4.1. Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers .... 327
  12.4.2. Importation From Canada ............................................................................ 330
  12.4.3. State Legislation of the Drug Channel ........................................................... 332
  12.4.4. Specialty Pharmacies’ Role in Cell and Gene Therapy Channels ................. 334
12.4.5. Controversy Over the 340B Program and Recent Manufacturer Actions .................................. 337
12.5. New Entrants and Potential Pharmacy Market Disruption .................................................................. 340
  12.5.1. Update on Amazon’s Potential Impact ......................................................................................... 340
  12.5.2. Venture-Backed Digital Pharmacies ............................................................................................... 342

Acronyms and Abbreviations ..................................................................................................................... 345

Endnotes .................................................................................................................................................... 346
LIST OF EXHIBITS

Exhibit 1: Timeline of DSCSA Requirements for Pharmacies (Dispensers), 2013 to 2023 ...........................................14
Exhibit 2: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2003 to 2025 ..............................................17
Exhibit 3: Variation in State Generic Substitution Policies, 2020 .................................................................................18
Exhibit 4: Top Traditional Therapy Categories, Generic Drugs As a Share of Prescriptions and Net Spending, 2019 .19
Exhibit 5: Specialty Prescriptions, Number and Share of Total, 2016 to 2020 .............................................................20
Exhibit 6: Top Specialty Therapy Categories, Generic Drugs As a Share of Prescriptions and Net Spending, 2019 ....23
Exhibit 7: Top Traditional Therapy Categories, Share of Net Spending, and Average Net Prescription Costs, 2019 ..24
Exhibit 8: Top Specialty Therapy Categories, Share of Net Spending, and Average Net Prescription Costs, 2018 .....24
Exhibit 9: Chain Drugstore Revenues, by Type of Merchandise, 2017 ........................................................................27
Exhibit 10: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2020 .............28
Exhibit 11: Average Wait Time for Prescription Pickup, by Retail Dispensing Format, 2020 .................................28
Exhibit 12: Average Annual Prescription Revenue per Pharmacy Outlet, by Retail Dispensing Format, 2020 ..........29
Exhibit 13: Top Four Reasons for Pharmacy Selection, by Dispensing Format, 2020 .....................................................30
Exhibit 14: Customer Satisfaction With Pharmacies, by Dispensing Format and Company, 2020 .........................30
Exhibit 15: Pharmacist Employment and Salary, by Practice Setting, 2019 .................................................................31
Exhibit 16: Share of Pharmacist Employment, by Industry, 2013 vs. 2019 .................................................................32
Exhibit 17: Pharmacists and Healthcare Workers, Change in Annual Average Salary, by Employer, 2014 to 2019 ....33
Exhibit 18: Pharmacist Employment, by Industry and Dispensing Format, 2019 vs. 2029 .............................................34
Exhibit 19: Insurance Coverage for Retail Clinics, 2010 to 2020 ..............................................................................35
Exhibit 20: Number of U.S. Retail Clinics, 2004 to 2021 ......................................................................................36
Exhibit 21: Providers of Medication Therapy Management Services, Medicare Part D, 2015 vs. 2019 ..................40
Exhibit 23: CPESN Networks and Pharmacies, 2018 to 2020 ....................................................................................41
Exhibit 24: Sites of Vaccine Administration for Medicare Beneficiaries, 2018 .............................................................43
Exhibit 25: Adult Influenza Vaccination, by Place of Vaccination, 2018-19 vs. 2020-21 .............................................44
Exhibit 26: Pharmacy Availability and Consumer Usage of Immunization, by Dispensing Format, 2016 vs. 2020 ....45
Exhibit 27: Total U.S. Pharmacy Industry Prescription Revenues, Prescriptions, and Locations, by Dispensing Format, 2020 ........................................................................................................46
Exhibit 28: Prescriptions, Annual Total and Growth, 2017 to 2020 ........................................................................47
Exhibit 29: 30-Day Equivalent Prescriptions, Annual Total and Growth, 2017 to 2020 .............................................48
Exhibit 30: 90-Day Prescriptions As a Percentage of Total Prescriptions, by Dispensing Format, 2017 to 2020 ......48
Exhibit 31: Pharmacy Industry Prescription Revenues, Annual Total and Growth, 2016 to 2020 .........................50
Exhibit 32: Largest 15 U.S. Pharmacies, by Total Prescription Revenues, 2020 ..........................................................51
Exhibit 33: Total Change in 30-Day Equivalent Prescriptions Dispensed and Prescription Revenues, by Pharmacy Type, 2010 vs. 2020 ...............................................................52
Exhibit 34: 30-Day Equivalent Prescriptions Dispensed per Location, by Dispensing Format, 2010 to 2020 ..........53
Exhibit 35: Year-over-Year Change in Weekly Number of 30-Day Equivalent Prescriptions Dispensed, January to December 2020 ..........................................................54
Exhibit 36: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2019 vs. 2020 .........................54
Exhibit 37: Prescription Dispensing Revenues, by Dispensing Format, 2019 vs. 2020 ........................................56
Exhibit 38: Year-Over-Year Change in Same-Store Prescription Count, by Chain, 2016 to 2020 .........................57
Exhibit 39: Walgreens Boots Alliance, U.S. Store Count, 2016 to 2020 ..............................................................58
Exhibit 40: Largest Regional Chain Drugstores, by Total Prescription Revenues, 2020 ......................................61
Exhibit 41: Pharmacy Locations Acquired, by Company, 2010 to 2020 .................................................................62
Exhibit 42: Number of Independent Pharmacies, 2001 to 2020 ..............................................................63
Exhibit 43: Pharmacy Franchise and Marketing Programs, 2020 .................................................................64
Exhibit 44: Share of Mail Pharmacy Dispensing Revenues, by Company, 2020 ..................................................68
Exhibit 45: Importance of Specialty Pharmacy Services to Patients, 2020 .........................................................71
Exhibit 46: Usage of Specialty Pharmacy Services by Patients, 2018 vs. 2020 ..................................................72
Exhibit 47: Specialty Prescription Dispensing Revenues, Annual Total and Growth, 2016 to 2020 .....................75
Exhibit 48: Specialty Prescription Dispensing Revenues As a Percentage of Total, 2013 to 2020 .......................76
Exhibit 49: Specialty Drugs As a Percentage of Payers’ Pharmacy Benefit Spending, by PBM, 2013 vs. 2019 ......76
Exhibit 50: Number of Pharmacy Locations With Specialty Pharmacy Accreditation, by Organization, 2015 to 2020 .................................................................77
Exhibit 51: Locations With URAC Specialty Pharmacy Accreditation, 2008 to 2020 .............................................78
Exhibit 52: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2020 ..........79
Exhibit 53: Merger and Acquisition Transactions, Specialty Pharmacy and Infusion Services, 2014 to 2020 ....80
Exhibit 54: Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2020 ....82
Exhibit 55: Share of Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2015 vs. 2020 ........................................................................83
Exhibit 56: Specialty Drug Prescription Revenues, by Dispensing Format, 2020 ..................................................84
Exhibit 57: Number of Private Specialty Pharmacies Ranked on Inc. 5000 List, 2012 to 2020 ..................................88
Exhibit 58: Retail Companies With Specialty Pharmacy Businesses, 2020 .........................................................90
Exhibit 59: Hospitals With a Specialty Pharmacy, by Number of Staffed Beds, 2015 vs. 2019 .......................92
Exhibit 60: Prescription Dispensing Revenues from Specialty Pharmacy, by Health System, 2020 .....................94
Exhibit 61: Health Systems’ Requirements for Employee Use of an In-House Pharmacy, 2020 ........................95
Exhibit 62: Percentage of Oncology Practices With In-Practice Oral Oncology Drug Dispensing, 2013 to 2019 ....97
Exhibit 63: Frequency of Manufacturer Contracting for Specialty Pharmacy Services, by Type of Service, 2019 ...104
Exhibit 64: Example of Specialty Hub Workflow ...................................................................................................106
Exhibit 65: Leading Specialty Hub Services Providers and Ownership, 2020 .....................................................107
Exhibit 66: Chapter Coverage of Flows in the U.S. Distribution and Reimbursement System ..........................108
Exhibit 67: Comprehensive Health Insurance Enrollment, by Payer, 2018 to 2020 ..........................................110
Exhibit 68: Change in Membership, Commercial vs. Managed Medicaid, by Insurer, 2020 ............................110
Exhibit 69: Medicaid Enrollment, 2005 to 2020 ................................................................. 111
Exhibit 70: Share of U.S. National Health Expenditures, by Category, 2019 .......................... 112
Exhibit 71: Share of U.S. National Health Expenditures, by Major Spending Category, 1979 to 2019 . . 113
Exhibit 72: Growth Rate in U.S. National Health Expenditures, by Major Spending Category, 2010 to 2019 ...... 114
Exhibit 73: Outpatient Prescription Drug Expenditures, by Source of Payment, 2019 ......................... 115
Exhibit 74: Outpatient Prescription Drugs As a Share of Payer’s Total Health Expenditures, by Payer, 2005 to 2019 ................................................................. 115
Exhibit 75: Outpatient Prescription Drug Dispensing, by Source of Payment, 2019 ......................... 116
Exhibit 76: Prescription Expenses per Person, by Age, 2018 ......................................................... 117
Exhibit 77: Change in Net Spending for Outpatient Prescription Drugs, by Payer, 2018 vs. 2019 ........... 117
Exhibit 78: Hospital Care vs. Prescription Drugs, Total Expenditures and Consumer Out-of-Pocket Spending, 2019 ................................................................. 119
Exhibit 79: Change in Commercial Payer Net Drug Spending, Traditional vs. Specialty Drugs, 2014 to 2019 .... 119
Exhibit 80: Change in Commercial Payer Net Drug Spending, Traditional vs. Specialty Drugs, by PBM, 2019 ...... 120
Exhibit 81: Components of Change in Net Commercial Payer Drug Spending, by PBM, 2019 .................. 122
Exhibit 82: Components of Change in Net Specialty Drug Spending, by PBM, 2018 ........................... 123
Exhibit 83: Cash-Pay Prescriptions As a Share of Total Prescriptions, 2017 to 2020 ......................... 124
Exhibit 84: Relative Cash Prescription Prices for Generic and Brand-Name Drugs, by Dispensing Format, 2019.... 125
Exhibit 85: Pharmacy Benefit Management Contracting Approach, by Company Size, 2017 vs. 2020 ........ 132
Exhibit 86: Medicare Part D Plan Sponsor Use of PBMs, by Benefit Management Service, 2016 ........... 134
Exhibit 87: Number of Unique Products on PBM Formulary Exclusion Lists, Single-Source vs. Multiple-Source, 2014 to 2020................................................................. 136
Exhibit 88: Number of Products on PBM Formulary Exclusion Lists, by PBM, 2012 to 2021 ................. 136
Exhibit 89: Formulary Exclusions for Specialty Drugs, Medicare Part D Plans, 2019 ......................... 139
Exhibit 90: Prevalence of Utilization Management Tools to Manage Specialty Drug Costs, Employer-Sponsored Health Plans, 2016 vs. 2020 ................................................................. 141
Exhibit 92: PBM Market Share, by Total Equivalent Prescription Claims Managed, 2020 ..................... 143
Exhibit 93: Largest Pharmacy Services Administrative Organizations, by Members and Ownership, 2020 .... 153
Exhibit 94: Key Components of PBM Compensation ................................................................. 155
Exhibit 95: Average PBM Spread in Medicaid Managed Care, by State, 2018-19 ............................... 157
Exhibit 96: Average Pharmacy Reimbursement and PBM Spread, by Type of Prescription, Maryland Medicaid Managed Care, 2019 ................................................................. 157
Exhibit 97: Imatinib Mesylate, Fee-for-Service and Managed Medicaid Payments vs. Pharmacy Acquisition Cost, 2016 to 2020 ................................................................. 158
Exhibit 98: Plan Sponsors’ Perceived Transparency of PBM Relationship, by PBM Size, 2018 ............... 160
Exhibit 99: Common Pharmacy Benefit Plan Designs ........................................................................... 162
Exhibit 100: Share of Employees Covered by a High Deductible Health Plan, 2006 to 2020 .................. 163
Exhibit 130: Distribution of Annual Patient Out-of-Pocket Spending, by Type of Health Plan, 2019
Exhibit 131: Cost Sharing Waived for Medications to Treat Chronic Conditions, by Company Size, 2020
Exhibit 132: Type of Cost Sharing for Out-of-Pocket Prescription Spending, 2015 to 2019
Exhibit 133: Type of Cost Sharing for Out-of-Pocket Prescription Spending on Specialty Drugs, by Therapy and Average Cost, 2019
Exhibit 134: Medicare Part D, Share of Benefit Liability, by Payer, 2007 vs. 2017
Exhibit 135: New-to-Product Prescription Abandonment, by Patient Out-of-Pocket Cost, 2019
Exhibit 136: Consumer Understanding of Health Insurance Terms, 2019
Exhibit 137: CVS Health, Quarterly Retail Prescription Revenues, 2014 to 2020
Exhibit 138: Summary of Pharmacy Benefit Network Design Options
Exhibit 139: Average Distance to Nearest Pharmacy, by Core Based Statistical Area (CBSA) Status, 2017
Exhibit 140: Medicare Part D PDPs With Preferred Pharmacy Networks, 2011 to 2021
Exhibit 141: Participation As a Preferred Cost Sharing Pharmacy in Selected Medicare Part D PDPs, by Retail Chain, 2021
Exhibit 142: Enrollment in Medicare Part D PDPs with Preferred Cost Sharing Networks, by Pharmacy Chain, 2020 vs. 2021
Exhibit 143: Participation As a Preferred Cost Sharing Pharmacy in Selected Medicare Part D PDPs, by PSAO, 2021
Exhibit 144: Share of Large Employers with a Narrow Retail Pharmacy Network, 2013 to 2020
Exhibit 145: Mandatory Mail Pharmacy Utilization for Maintenance Medications, Employer-Sponsored Plans, 2013 to 2018
Exhibit 146: TRICARE, Net Spending on Outpatient Prescriptions, by Dispensing Outlet, 2012 to 2019
Exhibit 147: Payers’ Perceived Lowest-Cost Site of Care for Specialty Dispensing, 2018
Exhibit 149: Drug Sourcing for Infused Therapies, Oncology vs. Non-Oncology, by Practice Type and Source, 2019
Exhibit 150: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost
Exhibit 151: Pharmacy AWP Reimbursement and Copayments for Brand-Name Prescriptions, by Dispensing Format, 2020
Exhibit 152: AWP Reimbursement Difference, Retail vs. Mail Pharmacies, 2008 to 2020
Exhibit 153: Use of Financial Incentives for Mail Pharmacy Utilization for Maintenance Medications, Employer-Sponsored Plans, by Company Size, 2019
Exhibit 154: AWP Reimbursement and Copayments for Generic Prescriptions, by Dispensing Format, 2020
Exhibit 155: Pharmacy Reimbursement in Medicaid Program, Fee-for-Service vs. Managed Care
Exhibit 156: Pharmacy Reimbursement Methodology and Dispensing Fee, Largest Fee-for-Service State Medicaid Programs, 2020
Exhibit 157: PBM Rebate Arrangements for Traditional and Specialty Medications in Employer-Sponsored Plans, by Employer Size, 2020
Exhibit 158: Total PBM-Negotiated Rebates and Share Retained, Diabetes Drugs in Nevada, 2017 to 2019 ........240
Exhibit 159: PBM Administrative Fees As a Percentage of WAC, by Company, 2019 .................................................241
Exhibit 160: Value of Direct and Indirect Remuneration (DIR) in Medicare Part D, 2012 to 2020 ........................................242
Exhibit 161: Medicare Part D, Value of Direct and Indirect Remuneration (DIR), by Source, 2013 vs. 2020 .................243
Exhibit 162: Medicaid Program, Gross Prescription Spending and Prescriptions, Fee-For-Service vs. Managed Care, 2015 vs. 2019 ................................................................................................................247
Exhibit 163: Largest Managed Medicaid Organizations, by Enrollment, 2020 ..............................................................247
Exhibit 164: Medicaid, Gross vs. Net Spending on Outpatient Drugs, 2015 to 2019 .........................................................249
Exhibit 165: Brand-Name Drugs, Change in Average List and Net Prices, 2014 to 2020 ...................................................251
Exhibit 166: Change in List vs. Net Price, by Manufacturer, 2019 .................................................................................252
Exhibit 167: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, 2016 to 2020 ..................................................................................................................254
Exhibit 168: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, by Source, 2020 ...................................................................................................................256
Exhibit 169: CVS Health, Brand-Name Rebates Per Commercial Life and Share Retained by PBM, 2011 to 2020 ..257
Exhibit 170: Large Employers’ Point-of-Sale Rebate Programs, 2019 to 2021 ..............................................................259
Exhibit 171: Prescription Economics for a Third-Party Payer—Traditional Brand-Name Drug Example .......................264
Exhibit 172: Prescription Economics for a Third-Party Payer—Traditional Brand-Name Drug Example in a High-Deductible Health Plan ..................................................................................................................266
Exhibit 173: Prescription Economics for a Third-Party Payer—Traditional Brand-Name Drug Example in High-Deductible Health Plan with Point-of-Sale Rebates ........................................................................................................267
Exhibit 174: Prescription Economics for a Third-Party Payer—Specialty Brand-Name Drug Example .......................268
Exhibit 175: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, 2020 ...........................................270
Exhibit 176: Determination of a Pharmacy’s Brand-Name Drug Acquisition Cost from a Wholesaler ..................275
Exhibit 177: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of Pharmacies, 2020 ..................................................................................................................................277
Exhibit 178: Share of U.S. Generic Purchasing Volume, by Organization, 2020 ............................................................279
Exhibit 179: Overall Gross Margins for Chain and Independent Drugstores, 2006 to 2019 .................................283
Exhibit 180: Total Gross Profits for Chain and Independent Drugstores, 2015 to 2019 ................................................283
Exhibit 181: Overall Gross Margins for Chain and Independent Drugstores, by Company, 2020 .........................284
Exhibit 182: Prescriptions As a Percentage of Revenues, by Company, 2013 to 2020 ..................................................285
Exhibit 183: Components of Overall Average Pharmacy Cost of Dispensing, 2019 .....................................................286
Exhibit 184: Example of Brand-Name Prescription Economics for a Retail Pharmacy ..............................................287
Exhibit 185: Independent Pharmacies, Average Per-Prescription Gross Profits and Margins, 2015 to 2019 ............288
Exhibit 186: Diplomat Pharmacy, Per-Prescription Gross Profits and Margins, 2014 to 2019 .................................289
Exhibit 187: Top Three PBMs, Sources of Gross Profit, 2015 vs. 2020 .................................................................290
Exhibit 188: Effect of Brand-Name List Price Increases on a Prescription’s Gross Profit .........................................291
Exhibit 189: Median Generic Price Relative to Brand Price Before Generic Entry, by Number of Manufacturers ...294
Exhibit 190: Imatinib Mesylate, Pharmacy Acquisition Cost, Brand vs. Generic, 2016 to 2021 ...............................295
Exhibit 191: Lifecycle of Per-Prescription Gross Profits, Brand vs. Multisource Generic ........................................296
Exhibit 192: Median AWP Discount for Generic Drugs Sold to Retail Pharmacies, by Number of Manufacturers, 2020 .................................................................................................................. 298
Exhibit 193: Net Value of Pharmacy DIR Fees in Medicare Part D, 2013 to 2020 ...................................................... 300
Exhibit 194: 340B Drug Pricing Program, Purchases by Covered Entities, 2014 to 2020 ............................................. 304
Exhibit 195: 340B Contract Pharmacy Locations, 2010 to 2020 .............................................................................. 305
Exhibit 196: 340B Covered Entities, by Number of Contract Pharmacies, 2020 ......................................................... 306
Exhibit 197: 340B Contract Pharmacy Locations, by Company, 2020 ................................................................. 306
Exhibit 198: 340B Contract Pharmacy Locations, by Chain, 2013 vs. 2020 ............................................................... 307
Exhibit 199: Largest Specialty Pharmacies, 340B Contract Pharmacy Locations and Relationships, 2020 ........ 308
Exhibit 200: Flow of Funds and Product for a 340B Contract Pharmacy Network .................................................... 309
Exhibit 201: 340B Prescription Economics for a Covered Entity, a Contract Pharmacy, and a Patient—Specialty Brand-Name Drug Example ........................................................................................................... 312
Exhibit 202: Total Gross Profits from 340B Contract Pharmacy, by Company, 2020 ..................................................... 314
Exhibit 203: Actual and Projected Growth Rates in National Health and Outpatient Prescription Drug Expenditures, 2015 to 2025 .................................................................................................................................................. 315
Exhibit 204: Weekly Change in Outpatient Visits, 2020 ......................................................................................... 316
Exhibit 205: Total Brand Revenues Lost to Generic Launches, by Product Type, 2016 to 2025 .................. 317
Exhibit 206: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2015 to 2025 ............. 318
Exhibit 207: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, Oral vs. Injectable, 2015 to 2021 .................................................................................................................................................. 321
Exhibit 208: Generic Drug Approvals, FDA, 2014 to 2020 ......................................................................................... 322
Exhibit 209: Number of U.S. Biosimilar Approvals, 2015 to 2020 ........................................................................ 323
Exhibit 210: Vertical Business Relationships Among Insurers, PBMs, Specialty Pharmacies, and Providers, 2021 .. 327
Exhibit 211: Venture Capital-Backed Digital Pharmacies and Total Funding, 2021 ..................................................... 343